Fed. Circ. Axes Teva Antibody IP But Allows Treatment Patents
The Federal Circuit on Monday upheld the Patent Trial and Appeal Board's decision to invalidate patents covering the antibodies in Teva's migraine treatment Ajovy, but rejected Eli Lilly's bid to invalidate...To view the full article, register now.
Already a subscriber? Click here to view full article